ViewRay(OTC) VRAY

Market CapN/A

Since IPO (2015)-100%

5 Year-100%

1 Year+0%

1 Month+0%

N/A

ViewRay last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-28

ViewRay stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-21
1 month	+0%	USD 0.00	2026-07-29
3 month	+0%	USD 0.00	2026-05-28
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-28
3 year	-99.99%	USD 0.01	2023-08-29
5 year	-100%	USD 5.92	2021-08-27
Since inception	-100%	USD 5.00	2015-08-10

ViewRay Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$105.87M

Net Income (TTM)

-$114.17M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 8, 2024

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 8, 2024

VRAY News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ViewRay

ViewRay, Inc. is a medical device company specializing in the design, manufacture, and marketing of MRI-guided radiation therapy systems. The company's flagship product, the MRIdian A3i, offers real-time 3D tissue tracking and automated beam control for cancer treatment.

Products and Services

MRIdian A3i: MRI-guided radiation therapy system
Real-time 3D tissue tracking technology
Automated beam control for precise treatment

Growth Outlook

Market demand for advanced cancer treatment technologies is increasing
Potential for expansion in international markets
Focus on innovation may lead to new product developments

Financial Highlights

Q1 2023 revenue of $22.5 million, down from $34.7 million in Q4 2022
Net income for Q1 2023 was -$28.9 million, reflecting ongoing operational challenges
Cash and cash equivalents at $81.3 million as of March 31, 2023

ViewRay, Inc. operates in a challenging environment, having recently transitioned from Chapter 11 to Chapter 7 bankruptcy. Despite these difficulties, the company continues to focus on its innovative MRI-guided radiation therapy systems, which are crucial for treating various types of cancer. The recent quarterly financials indicate a decline in revenue, highlighting the need for strategic adjustments. However, the significant cash reserves may provide a buffer for future operations and potential recovery efforts. The growing market for advanced cancer treatment technologies presents opportunities for ViewRay, should it successfully navigate its current challenges.

AI Generated • Aug 31, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

295

CEO

Scott William Drake

Website

www.viewray.com

Headquarters

Oakwood, OH 44146, US

VRAY Financials

Key Financial Metrics (TTM)

Gross Margin

9.83%

Operating Margin

-104.81%

Net Income Margin

-105.01%

Return on Equity

-85.17%

Return on Capital

-63.52%

Return on Assets

-39.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$8.52M

Operating Income

-$107.47M

EBITDA

-$98.48M

Operating Cash Flow

-$112.92M

Capital Expenditure

-$3.86M

Free Cash Flow

-$116.78M

Cash & ST Invst.

$81.29M

Total Debt

$85.13M

ViewRay Performance Analysis

ViewRay annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 70,119,000	N/A
2022	2022-12-31	USD 102,206,000	45.8%

ViewRay sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2022-06-30	17.3%
Q3	2022-09-30	19.6%
Q4	2022-12-31	31.0%
Q1	2023-03-31	-35.0%

ViewRay annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.67	N/A
2022	2022-12-31	USD -0.59	-11.2%

ViewRay sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2022-06-30	-15.4%
Q3	2022-09-30	-6.7%
Q4	2022-12-31	6.3%
Q1	2023-03-31	-13.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2023YOY CHG

Revenue

$22.53M

+19.4%

Gross Profit

-$1.43M

-1621.3%

Gross Margin

-6.35%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

295

N/A

Net Income

-$30.71M

-27.6%

EBITDA

-$25.27M

-7.7%

Quarterly Fundamentals

Name

Q1 2023YOY CHG

Total Cash

$81.29M

-54.9%

Total Debt

$85.13M

+26.4%

Accounts Receivable

$47.53M

+69.7%

Inventory

$42.19M

+61.8%

Long Term Debt

$4.44M

-92.2%

Short Term Debt

$80.69M

+654.9%

Return on Assets

-39.55%

N/A

Return on Invested Capital

-61.28%

N/A

Free Cash Flow

-$54.78M

-63.0%

Operating Cash Flow

-$53.60M

-65.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MDGSXylo Technologies Ltd.

MDGSXylo Technologies Ltd.$2.36+10.28%

NBRVFNabriva Therapeutics plc

NBRVFNabriva Therapeutics plc$0.00+0.00%

RHEPRegional Health Properties, Inc.

RHEPRegional Health Properties, Inc.$1.07+1.90%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About VRAY

What is the current price of ViewRay?

ViewRay is trading at N/A per share.

What is the 52-week range for ViewRay?

Over the past 52 weeks, ViewRay has traded between N/A and N/A.

How much debt does ViewRay have?

As of the most recent reporting period, ViewRay reported total debt of $86.40M.

How much cash does ViewRay have on hand?

ViewRay reported $135.96M in cash and cash equivalents in its most recent financial results.

What is ViewRay’s dividend yield?

ViewRay does not currently have a dividend yield.

ViewRay(OTC) VRAY

ViewRay Financials at a Glance

VRAY News

Why ViewRay Stock Is Sinking Today

Why ViewRay Crushed the Market on Thursday

Why ViewRay Stock Vaulted Higher Today

Why ViewRay Stock Got Crushed Today

Why ViewRay Stock Dropped Today

Why ViewRay Stock Is Tanking Today

Why Lands' End, Audentes Therapeutics, and ViewRay Jumped Today

Why ViewRay Stock Is Shooting Higher Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ViewRay

VRAY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ViewRay Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VRAY

What is the current price of ViewRay?

What is the 52-week range for ViewRay?

How much debt does ViewRay have?

How much cash does ViewRay have on hand?

What is ViewRay’s dividend yield?

Premium Investing Services